Research in Medical Imaging

Dr. Ulrike Dydak 's research interest is the methodological development and application of magnetic resonance imaging (MRI) to study human health. In particular she uses Magnetic Resonance Spectroscopy (MRS) for the noninvasive in-vivo assessment of metabolism to investigate neurodegeneration, influences of toxins, and to monitor treatment response. Special emphasis of her work lies on the development of the in-vivo detection and quantification of γ-aminobutyric acid (GABA), an inhibitory neurotransmitter, to study manganese-induced parkinsonian neurotoxicity and idiopathic Parkinson Disease. A second focus lies on the development of whole-liver phosphorous (31P) magnetic resonance spectroscopic imaging of the human liver to improve treatment monitoring in liver cancer. Dr. Dydak holds an adjunct appointment at the Department of Radiology and Imaging Sciences at IU School of Medicine, where part of her research lab is located.

Dr. Uzay Emir’s expertise lies in the development and clinical translation of magnetic resonance spectroscopy (MRS) techniques at clinical (3T) and ultra-high field (UHF>3T) magnetic fields. He have used these systems at both 3T and 7T to quantify various brain metabolites, including neurotransmitters (γ-amino butyric acid, GABA, and glutamate, Glu) in Parkinson’s Disease (PD); antioxidants (glutathione, GSH, and ascorbate, Asc) in aging; and oncometabolites (2 hydroxyglutarate, 2-HG, and lactate, Lac) in patients with glioma. His research interests include (1) studying the neurochemical basis of brain plasticity; (2) developing methods for profiling psychiatric disorders and psychoactive drug discovery; (3) neurochemical profiling of brain cancer; and (4) unraveling the neurochemical mechanisms of BOLD-fMRI signal.

Dr. Shuang Liu's research interests include receptor-based target radiopharmaceuticals, new bifunctional chelators, development of new techniques for radiolabeling of small biomolecules, formulation development, design/synthesis/evaluation of metal complexes as MRI contrast agents for cardiac perfusion imaging, and coordination chemistry of radiopharmaceuticals. There have been tremendous research efforts from his research group in the development of novel radiotracers for early tumor detection and diagnosis of cardiovascular diseases.  These efforts rely on identification and the use of small biomolecules as “vehicles” to carry a diagnostic radionuclide to the tumor cells. Imaging with radiolabeled small biomolecules allows us to monitor the tumor biological changes at the molecular level.  Over the last 10 years, Dr. Liu has become the leader in radiolabeled cyclic RGD peptides as integrin αvβ3-specific SPECT and PET radiotracers for imaging the integrin expression αvβ3 in rapidly growing and metastatic tumors.  Dr. Liu is the author or co-author over 160 scientific publications, and has been granted 30 US patents and PCT applications.  Dr. Liu’s contributions also have significant impacts on inorganic chemistry, radiochemistry, radiopharmaceutical development, bioconjugates chemistry, molecular imaging, and nuclear medicine.  His research has been supported by grants from the National Institute of Health, Department of Energy, American Heart Association, and industry.

Dr. Pérez-Torres's research focuses on how radiation treatment affects the normal brain to develop better diagnostic MRI tools (is it tumor or just a treatment side effect?) and to potentially improve radiation therapy of brain tumors. His research (1) develops Magnetic Resonance Imaging (MRI) techniques – diffusion weighted imaging (DWI), perfusion, and magnetization transfer – in the characterization of normal tissue and tumors; (2) investigates radiation-induced necrosis and cognitive impairment; and (3) the characteristics of brain tumors in response to therapy using MRI.

Dr. Keith Stantz's research interests include: (1) developing photoacoustic computed tomographic (PCT) scanner and analytic methods for in vivo quantification of endogenous (hemoglobin) and exogenous (photoacoustic contrast agents) molecules, (2) developing a new PCT-S scanner for dynamic constrast-enhanced techniques (DCE-CT) for in vivo quantification of vascular physiology in mouse models of cancer, (3) discovering patterns of intra-tumor hemodynamics and oxygenation of cancer to different cancer angiogenic phenotypes, and (4) discovery of biological models linking anti-angiogenic therapeutic-driven hypoxia to cancer stem cells and metastasis.

Purdue University, School of Health Sciences, 550 Stadium Mall Drive, West Lafayette, IN 47907, (765) 494-1419, Fax: (765) 496-1377

© 2016 Purdue University| An equal access/equal opportunity university | Copyright Complaints | Maintained by HSCI

If you have trouble accessing this page because of a disability, please contact hsciwebhelp@purdue.edu.